Springer Nature, an academic publisher, is reviving its IPO plans, reported Bloomberg. The listing could take place as early as the first half of 2020. Springer Nature. In May 2018, BC Partners and Holtzbrinck postponed an IPO of Springer Nature, citing unfavorable market conditions. Owned by BC Partners and Holtzbrinck Publishing Group, Springer Nature is the publisher of Nature and Scientific American.
Canadian private equity firm Onex Corp has sold US$422 million of shares of Switzerland’s SIG Combibloc Group, a systems and solutions provider for aseptic carton packaging. In September 2018, Onex took SIG public on the SIX Swiss Exchange. PRESS RELEASE TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) — Onex Corporation (“Onex”) (TSX: ONEX) and its affiliated […]
San Francisco and Israel-based 89Bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis and other liver and metabolic disorders, has raised about $84.9 million for its IPO after pricing its over 5.3 million shares at $16 per share. The stock began trading November 11, 2019 on the NASDAQ under the ticker symbol "ETNB." BofA Securities, SVB Leerink and RBC Capital Markets are the lead underwriters. 89Bio's pre-IPO backers include OrbiMed Israel, OrbiMed US, Longitude Capital, RA Capital Management and Pontifax.
Toronto-based GFL Environmental Inc, a waste management company, has canceled its cross-border IPO after investors balked at paying the price range of the shares, reported Reuters. The media outlet noted that investors had pushed GFL to price the shares at $18 per share. As previously reported by PE HUB, GFL has priced its over 87 […]
Saudi Aramco said Nov. 3 that it plans to go public on the main market of the Tadawul. Saudi Aramco, considered the world’s most profitable company, is expected to price its IPO in December and begin trading on Dec. 11, the Financial Times reported.
Centogene, a company focused on rare diseases, is seeking to raise about $60 million for its IPO after pricing its 4 million shares at a price range between $14 and $16 per share. Centogene is planning on trading the stock on the NASDAQ under the ticker symbol "CNTG." SVB Leerink and Evercore ISI are the lead underwriters. Centogene's backers include TVM Capital Life Science.
Cabaletta Bio, a biotech company, has debuted its IPO after pricing its 6.8 million shares at $11 per share. The stock began trading October 25, 2019 on the NASDAQ under the ticker symbol "CABA." Morgan Stanley, Cowen and Evercore ISI are the lead underwriters. Cabaletta Bio's pre-IPO backers include 5 AM Ventures and Adage Capital Partners.
Progyny, a fertility benefits management company, has raised $130 million for its IPO after pricing its 10 million shares at $13 per share. The stock began trading October 25, 2019 on the NASDAQ under the ticker symbol "PGNY." JP Morgan, Goldman Sachs and BofA Securities are the lead underwriters. Progyny's pre-IPO backers include Kleiner Perkins, TPG Biotech and Union Grove Venture Partners.
Menlo Park, California-based Phathom Pharmaceuticals, a biopharmaceutical company focused on treating gastrointestinal diseases, has raised about $181.7 million for its IPO after pricing its over 9.5 million shares at $19 per share. The stock began trading October 25, 2019 on the NASDAQ under the ticker symbol "PHAT." Goldman Sachs, Jefferies and Evercore ISI are the lead underwriters. Phathom's pre-IPO backers include Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen.
Toronto-based GFL Environmental Inc, a waste management company, has priced its cross-border IPO of over 87 million shares at a price between US$20 and US$24 per share. GFL plans on listing the stock on the New York Stock Exchange and Toronto Stock Exchange under the ticker symbol “GFL.” J.P. Morgan, BMO Capital Markets, Goldman Sachs, […]